Open AccessMYCOPHENOLATE MOFETIL REDUCES THE RISK OF ACUTE REJECTION LESS IN AFRICAN-AMERICAN THAN IN CAUCASIAN KIDNEY RECIPIENTS1
Author(s) -
Eugene J. Schweitzer,
S. A. Yoon,
Jeffrey C. Fink,
Anne Wiland,
Lloyd L. Anderson,
Paul C. Kuo,
James W. Lim,
Lynt B. Johnson,
Alan C. Farney,
Matthew R. Weir,
Stephen T. Bartlett
Publication year - 1998
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-199801270-00017
Subject(s) - medicine , azathioprine , immunosuppression , relative risk , kidney transplantation , proportional hazards model , gastroenterology , population , transplantation , incidence (geometry) , mycophenolic acid , surgery , confidence interval , physics , disease , environmental health , optics
Multicenter clinical trials have shown that mycophenolate mofetil (MMF) reduces the risk of acute rejection, but it is unknown whether African-Americans constitute a subgroup of recipients less likely to benefit from MMF.